2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-119667
    Enrasentan 167256-08-8 98.39%
    Enrasentan (SB 217242) is an endothelin (ET) receptor antagonist. Enrasentan has antihypertensive effects.
    Enrasentan
  • HY-119817
    Flosequinan 76568-02-0 99.95%
    Flosequinan is a balanced vasodilator. Flosequinan not only significantly reduces systemic vascular resistance, but also significantly reduces the beating component of left ventricular afterload, characteristic impedance and arterial wave reflection, which can be used in the research of acute heart failure.
    Flosequinan
  • HY-119961
    (+)-Mepivacaine 24358-84-7 98.70%
    (+)-Mepivacaine is a racemic isomer of Mepivacaine (HY-B0517), which has analgesic and vasoconstrictive activity. Mepivacaine is an amide type agent that temporarily causes local loss of consciousness. Mepivacaine binds to specific voltage-gated sodium channels on neuronal cell membranes, inhibiting sodium influx and membrane depolarization.
    (+)-Mepivacaine
  • HY-120514
    JNc-440 1119503-63-7 98.04%
    JNc-440 is a potent antihypertensive agent. JNc-440 can enhance the interaction of TRPV4 and Ca2+-activated potassium channel 3 (KCa2.3) in endothelial cells. JNc-440 can also enhance vasodilation, and exerted antihypertensive effects in mice.
    JNc-440
  • HY-120960
    N-Arachidonoyl-L-serine 187224-29-9 98%
    N-Arachidonoyl-L-serine (ARA-S) is an endocannabinoid. N-Arachidonoyl-L-serine induces phosphorylation of Akt and MAPK in endothelial cells. N-Arachidonoyl-L-serine also induces endothelium-dependent vasodilation in isolated rat mesenteric and abdominal aortas. N-Arachidonoyl-L-serine exhibits neuroprotective effects after traumatic brain injury by reducing apoptosis. N-Arachidonoyl-L-serine promotes the opening of KV7.1/KCNE1 channels in mammalian cells and shortens the action potential duration in cardiomyocytes. N-Arachidonoyl-L-serine may be used in research on cardiovascular and cerebrovascular diseases and neurological disorders.
    N-Arachidonoyl-L-serine
  • HY-120980
    Thromboxane B1 64626-32-0 98%
    Thromboxane B1 (TXB1) is a stable, inactive endogenous metabolite of Thromboxane A1 (TXA1).
    Thromboxane B1
  • HY-121045
    Bunitrolol 34915-68-9
    Bunitrolol hydrochloride is an orally active β-adrenergic blocker that has a high affinity for β-adrenergic receptors. Bunitrolol hydrochloride exerts significant β-receptor antagonist activity and has weak α1-blocking activity. Bunitrolol hydrochloride is mainly used in the study of cardiovascular diseases such as hypertension and angina pectoris, and is also used in placental transport research.
    Bunitrolol
  • HY-121385
    Hydroxy bosentan 253688-60-7 ≥98.0%
    Hydroxy bosentan (Ro 48-5033) is a primary metabolite of Bosentan (BOS) metabolized by the cytochrome P450 system in the liver. Ro 48-5033 assists BOS pharmacologically, retaining 10%-20% activities.
    Hydroxy bosentan
  • HY-121710
    MonoHER 23869-24-1
    MonoHER (7-Monohydroxyethylrutoside) is a Carbonyl reductase 1 (CBR1) inhibitor and can be used as a cardioprotective agent. MonoHER inhibits the activity of CBR1 V88 and CBR1 I88 in a concentration-dependent manner.
    MonoHER
  • HY-122033
    MK-0448 875562-81-5 99.79%
    MK-0448 is a specific Kv1.5 inhibitor used in the research of atrial fibrillation.
    MK-0448
  • HY-122592
    Zifaxaban 1378266-98-8 98.37%
    Zifaxaban is an orally active, competitively and selective Factor Xa (FXa) inhibitor with an IC50 of 11.1 nM for human FXa. Zifaxaban shows >10000-fold greater selectivity than other serine proteases. Zifaxaban can be used for the arterial and venous thrombosis research.
    Zifaxaban
  • HY-122915
    Zedoarondiol 98644-24-7 98.99%
    Zedoarondiol, a sesquiterpene lactone compound, with antioxidant and anti-inflammatory activity. Zedoarondiol can be used for atherosclerosis research.
    Zedoarondiol
  • HY-122951
    Eburicoic acid 560-66-7 98.61%
    Eburicoic acid protects the liver from CCl4-induced hepatic damage via antioxidant and anti-inflammatory mechanisms. And Eburicoic acid has antidiabetic and antihyperlipidemic effects.
    Eburicoic acid
  • HY-123179
    Mefruside 7195-27-9 99.9%
    Mefruside is an orally active diuretic and has a mild hypotensive effect. Mefruside inhibits the synthesis of urea in an isolated rat liver perfusion model. Mefruside can be used in studies of oedema and hypertension.
    Mefruside
  • HY-123983
    HS56 922050-57-5 99.6%
    HS56 is an ATP-competitive dual Pim/DAPK3 inhibitor with Ki values of 0.26, 0.208, 2.94, and ＞100 μM for DAPK3, Pim-3, Pim-1, and Pim-2, respectively. HS56 inhibits LC20 phosphorylation and smooth muscle contraction. HS56 decreases blood pressure in spontaneously hypertensive mice. HS56 can be used in research of hypertension.
    HS56
  • HY-124031
    Lobetyolinin 142451-48-7 99.06%
    Lobetyolinin is a polyacetylene compound. Lobetyolinin can be extracted from the traditional Chinese medicine Codonopsis pilosula. Lobetyolinin has antiarrhythmic effects. Lobetyolinin can be used in liver cancer research.
    Lobetyolinin
  • HY-124428
    ASP6537 524699-72-7 99.02%
    ASP6537 is a potent and selective rhCOX-1 inhibitor with an IC50 of 0.703 nM. ASP6537 has the potential for cardiovascular disease research.
    ASP6537
  • HY-124470
    Amisometradine 550-28-7 98%
    Amisometradine is an orally active aminouracil diuretic with a diuretic potency approximately 40% that of Mersalyl (HY-108868) (when administered intramuscularly). Amisometradine exerts its effects by promoting the excretion of sodium, chloride and a small amount of potassium, exhibits significant therapeutic effects in heart failure models, and has good tolerance with long-term administration. Compared with drugs of the same class, Amisometradine causes fewer gastrointestinal reactions; its minor side effects mainly include nausea, vomiting, diarrhea, tinnitus and deafness, and are usually not accompanied by proteinuria or abnormalities in blood and urine indicators. Amisometradine is an important tool for the study of heart failure and related diuretic mechanisms.
    Amisometradine
  • HY-125095
    Yonkenafil hydrochloride 804519-64-0 99.43%
    Yonkenafil (Tunodafil) hydrochloride, a novel phosphodiesterase 5 (PDE5) inhibitor, is effective in reducing cerebral infarction, neurological deficits, edema, and neuronal damage in the infarcted area. Yonkenafil (Tunodafil) hydrochloride may improve cognitive function by modulating neurogenesis and has a potential therapeutic effect on Alzheimer's disease.
    Yonkenafil hydrochloride
  • HY-125108
    PHPS1 sodium 1177131-02-0 99.93%
    PHPS1 sodium is a potent and selective Shp2 inhibitor with Kis of 0.73, 5.8, 10.7, 5.8, and 0.47 μM for Shp2, Shp2-R362K, Shp1, PTP1B, and PTP1B-Q, respectively.
    PHPS1 sodium
Cat. No. Product Name / Synonyms Application Reactivity